Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein; Ulrike Pötschger; Dominique Valteau‐Couanet; Roberto Luksch; Victoria Castel; Shifra Ash; Geneviève Laureys; Penelope Brock; Jean Michon; Cormac Owens; Toby N. Trahair; Gcf Chan; Ellen Ruud; Henrik Schrøeder; Maja Beck‐Popovic; G. Schreier; Hans Loibner; Peter F. Ambros; Keith Holmes; Maria Rita Castellani; Mark N. Gaze; Alberto Garaventa; Andrew D.J. Pearson; Holger N. Lode

doi:10.3390/cancers12020309

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

< 0.001, HR 2.665) as risk factors for relapse or progression. Results suggest an important role for dinutuximab beta-based immunotherapy within the treatment concepts applied in HR-NBL1/SIOPEN.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ladenstein et al. (2020) studied this question.

synapsesocial.com/papers/6a025a6753dafdb12211a5d6 https://doi.org/10.3390/cancers12020309

View Full Paper

Ask AI

Bookmark

Share

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ask about this paper

Abstract

Discussion

Cite This Study

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading